FMP
VanEck Pharmaceutical ETF
PPH
NASDAQ
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
85.31 USD
-1.17 (-1.37%)
Zacks Investment Research
Aug 14, 2024
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
ETF Trends
Aug 14, 2024
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
Seeking Alpha
Jul 18, 2024
The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat recession-proof, but high costs and regulatory risks are potential drawbacks.
Zacks Investment Research
Jul 9, 2024
Launched on 12/20/2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Zacks Investment Research
May 9, 2024
The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
ETF Trends
May 7, 2024
Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.
Zacks Investment Research
May 7, 2024
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
ETF Trends
Apr 30, 2024
Weight-loss drugs, including Ozempic, are reshaping consumer habits. Additionally, they are providing some ballast to what's recently been a sluggish healthcare investment thesis.
Seeking Alpha
Apr 23, 2024
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson, with potential for future growth.
Zacks Investment Research
Apr 17, 2024
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.